FENNEC PHARMACEUTICALS INC. financial data

Symbol
FENC on Nasdaq
Location
Research Triangle Park, NC
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 519% % -21%
Debt-to-equity -882% % 43%
Return On Equity 117% % 291%
Return On Assets -15% % -620%
Operating Margin -12% % -452%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 28,116,829 shares 2.5%
Common Stock, Shares, Outstanding 28,062,000 shares 2.3%
Entity Public Float $82,178,541 USD -40%
Common Stock, Value, Issued $147,652,000 USD 1.5%
Weighted Average Number of Shares Outstanding, Basic 27,889,000 shares 1.9%
Weighted Average Number of Shares Outstanding, Diluted 27,889,000 shares 1.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $38,790,000 USD -21%
Research and Development Expense $280,000 USD -3.1%
Selling and Marketing Expense $16,455,000 USD -10%
General and Administrative Expense $24,049,000 USD -6.9%
Operating Income (Loss) $4,663,000 USD -377%
Nonoperating Income (Expense) $1,912,000 USD 32%
Net Income (Loss) Attributable to Parent $6,940,000 USD -513%
Earnings Per Share, Basic 0 USD/shares -733%
Earnings Per Share, Diluted 0 USD/shares -111%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $21,947,000 USD -46%
Other Assets, Current $898,000 USD 64%
Assets, Current $46,064,000 USD -21%
Other Assets, Noncurrent $743,000 USD -22%
Assets $49,261,000 USD -16%
Accounts Payable, Current $5,866,000 USD 52%
Accrued Liabilities, Current $3,701,000 USD 12%
Contract with Customer, Liability, Current $248,000 USD 0%
Liabilities, Current $9,815,000 USD 32%
Contract with Customer, Liability, Noncurrent $24,561,000 USD 0%
Liabilities $53,753,000 USD -16%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,243,000 USD 0%
Retained Earnings (Accumulated Deficit) $224,636,000 USD -3.2%
Stockholders' Equity Attributable to Parent $4,492,000 USD 13%
Liabilities and Equity $49,261,000 USD -16%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,318,000 USD -111%
Net Cash Provided by (Used in) Financing Activities $359,000 USD
Common Stock, Shares, Issued 28,062,000 shares 2.3%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $3,959,000 USD -110%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $21,947,000 USD -46%
Deferred Tax Assets, Valuation Allowance $52,358,000 USD 29%
Deferred Tax Assets, Gross $52,384,000 USD 29%
Operating Lease, Liability $7,000 USD
Lessee, Operating Lease, Liability, to be Paid $5,000 USD
Operating Lease, Liability, Current $2,000 USD -90%
Lessee, Operating Lease, Liability, to be Paid, Year Two $2,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $5,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $13,219,000 USD -64%
Deferred Tax Assets, Net of Valuation Allowance $26,000 USD 0%